Evidence map›Paper›PMID 35631330›Full record

ReviewPharmaceuticals (Basel, Switzerland)2022

Drug Candidates for Autoimmune Diseases.

Sabrina Saurin, Myriam Meineck, Gerhard Erkel, Till Opatz, Julia Weinmann-Menke, Andrea Pautz

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Anti-Inflammatory Activity of Peptides fromFoods (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sabrina Saurin1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.ORCID 0000-0003-0222-2435
Myriam Meineck1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.
Gerhard ErkelDepartment of Molecular Biotechnology and Systems Biology, Technical University, 67663 Kaiserslautern, Germany.
Till OpatzDepartment of Chemistry, Johannes Gutenberg University, 55099 Mainz, Germany.ORCID 0000-0002-3266-4050
Julia Weinmann-Menke1st Department of Medicine, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.ORCID 0000-0001-7344-8381
Andrea PautzDepartment of Pharmacology, University Medical Center of the Johannes Gutenberg University, 55131 Mainz, Germany.ORCID 0000-0003-3969-0056

Funding

Deutsche Forschungsgemeinschaft ER 176/12-1Deutsche Forschungsgemeinschaft Op90/13-1Deutsche Forschungsgemeinschaft WE5779/4-1
6 · The paper itself

Abstract

Most of the immunosuppressive drugs used in the clinic to prevent organ rejection or to treat autoimmune disorders were originally isolated from fungi or bacteria. Therefore, in addition to plants, these are valuable sources for identification of new potent drugs. Many side effects of established drugs limit their usage and make the identification of new immunosuppressants necessary. In this review, we present a comprehensive overview of natural products with potent anti-inflammatory activities that have been tested successfully in different models of chronic inflammatory autoimmune diseases. Some of these candidates already have passed first clinical trials. The anti-inflammatory potency of these natural products was often comparable to those of established drugs, and they could be used at least in addition to standard therapy to reduce their dose to minimize unwanted side effects. A frequent mode of action is the inhibition of classical inflammatory signaling pathways, such as NF-κB, in combination with downregulation of oxidative stress. A drawback for the therapeutic use of those natural products is their moderate bioavailability, which can be optimized by chemical modifications and, in addition, further safety studies are necessary. Altogether, very interesting candidate compounds exist which have the potential to serve as starting points for the development of new immunosuppressive drugs.

Indexed as

autoimmunityinflammationmacrolactonenatural products

Identifiers

PMID35631330
PMCPMC9143092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.